KR101706255B1 - 재조합 항-표피 성장 인자 수용체 항체 조성물 - Google Patents

재조합 항-표피 성장 인자 수용체 항체 조성물 Download PDF

Info

Publication number
KR101706255B1
KR101706255B1 KR1020117007247A KR20117007247A KR101706255B1 KR 101706255 B1 KR101706255 B1 KR 101706255B1 KR 1020117007247 A KR1020117007247 A KR 1020117007247A KR 20117007247 A KR20117007247 A KR 20117007247A KR 101706255 B1 KR101706255 B1 KR 101706255B1
Authority
KR
South Korea
Prior art keywords
antibody
egfr
antibodies
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117007247A
Other languages
English (en)
Korean (ko)
Other versions
KR20110050542A (ko
Inventor
미켈 반달 페데르센
미카엘 크래프
아담 에스. 헤이
헬레 자코브센
Original Assignee
심포젠 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 심포젠 에이/에스 filed Critical 심포젠 에이/에스
Publication of KR20110050542A publication Critical patent/KR20110050542A/ko
Application granted granted Critical
Publication of KR101706255B1 publication Critical patent/KR101706255B1/ko
Assigned to 르 라보레또레 쎄르비에르 reassignment 르 라보레또레 쎄르비에르 권리의 전부이전등록 Assignors: 심포젠 에이/에스
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020117007247A 2008-08-29 2009-08-27 재조합 항-표피 성장 인자 수용체 항체 조성물 Active KR101706255B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200801202 2008-08-29
DKPA200801202 2008-08-29
US13639108P 2008-09-02 2008-09-02
US61/136,391 2008-09-02
PCT/DK2009/050217 WO2010022736A2 (en) 2008-08-29 2009-08-27 Recombinant anti-epidermal growth factor receptor antibody compositions

Publications (2)

Publication Number Publication Date
KR20110050542A KR20110050542A (ko) 2011-05-13
KR101706255B1 true KR101706255B1 (ko) 2017-02-14

Family

ID=41426867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117007247A Active KR101706255B1 (ko) 2008-08-29 2009-08-27 재조합 항-표피 성장 인자 수용체 항체 조성물

Country Status (15)

Country Link
US (1) US8663640B2 (https=)
EP (1) EP2331577B1 (https=)
JP (1) JP5719298B2 (https=)
KR (1) KR101706255B1 (https=)
CN (1) CN102137874B (https=)
AU (1) AU2009287163B2 (https=)
BR (1) BRPI0918768B1 (https=)
CA (1) CA2732856C (https=)
ES (1) ES2638579T3 (https=)
IL (1) IL210348A (https=)
MX (1) MX2011001927A (https=)
RU (1) RU2540146C2 (https=)
TW (1) TWI481412B (https=)
WO (1) WO2010022736A2 (https=)
ZA (1) ZA201100301B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
JP6039428B2 (ja) * 2010-03-04 2016-12-07 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ２抗体および組成物
CN105153307A (zh) * 2010-05-04 2015-12-16 梅里麦克制药股份有限公司 抗表皮生长因子受体(egfr)的抗体及其用途
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
CN105399831A (zh) * 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
JP6033783B2 (ja) * 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
US9233171B2 (en) 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
CN102397544A (zh) * 2011-11-25 2012-04-04 百泰生物药业有限公司 一种单克隆抗体用于治疗非小细胞肺癌的用途
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2844675B1 (en) * 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
US9429577B2 (en) 2012-09-27 2016-08-30 Biocare Medical, Llc Anti-uroplakin II antibodies systems and methods
WO2014064682A1 (en) * 2012-10-24 2014-05-01 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
WO2014151649A1 (en) * 2013-03-15 2014-09-25 Alper Biotech, Llc Monoclonal antibodies to egfr, and uses therefor
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
TW201925230A (zh) 2017-08-30 2019-07-01 丹麥商賽門弗鎮公司 以抗egfr療法治療癌症的組成物及方法
TR201906951A2 (tr) * 2019-05-09 2019-05-21 Ankara Ueniversitesi Rektoerluegue Enzimatik İşlemlerle Nar Suyu Kusurlarının Giderilmesi İçin Yöntem
EP4243870A4 (en) * 2020-11-13 2024-12-18 Sab, Llc UNGLILATE-DERIVED POLYCLONAL IMMUNGLOBULIN SPECIFIC TO EGFR AND USES THEREOF
CN116333120B (zh) * 2021-12-16 2024-03-05 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032961A1 (en) 2002-10-10 2004-04-22 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
EP0655924A4 (en) 1992-06-30 1996-09-11 Oncologix Inc A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.
EP0708659A4 (en) * 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDES
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1314404A (zh) 2000-03-22 2001-09-26 上海博德基因开发有限公司 一种新的多肽——人调控转录因子15和编码这种多肽的多核苷酸
CN1432064A (zh) 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
ES2398099T3 (es) 2001-02-19 2013-03-13 Merck Patent Gmbh Anticuerpos anti-EGFR modificados con inmunogenicidad reducida
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1482043A4 (en) 2002-03-01 2005-08-10 Japan Enviro Chemicals Ltd FOR BINDING TO ENVIRONMENTAL MORNES, PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
EP1511769A2 (en) 2002-05-15 2005-03-09 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
US20060275766A1 (en) 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US7655751B2 (en) 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
WO2006009694A2 (en) 2004-06-14 2006-01-26 Imclone Sysetms Incorporated Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
MX2007009963A (es) 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
KR20080003422A (ko) 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
EP1877083A2 (en) 2005-04-27 2008-01-16 Welson Pharmaceuticals, Inc. Antibodies for the treatment of cancers
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
JP2009528828A (ja) 2006-03-06 2009-08-13 シムフォゲン・アクティーゼルスカブ 消化器多核体ウイルス感染症の治療のための組み換えポリクローナル抗体
PT2121920E (pt) * 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
JP6033783B2 (ja) * 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032961A1 (en) 2002-10-10 2004-04-22 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy

Also Published As

Publication number Publication date
RU2540146C2 (ru) 2015-02-10
JP2012500814A (ja) 2012-01-12
US20110229463A1 (en) 2011-09-22
AU2009287163B2 (en) 2014-11-13
TWI481412B (zh) 2015-04-21
IL210348A0 (en) 2011-03-31
CA2732856A1 (en) 2010-03-04
WO2010022736A3 (en) 2010-04-22
JP5719298B2 (ja) 2015-05-13
EP2331577A2 (en) 2011-06-15
AU2009287163A1 (en) 2010-03-04
TW201010726A (en) 2010-03-16
CN102137874A (zh) 2011-07-27
CA2732856C (en) 2018-08-28
BRPI0918768A2 (pt) 2015-12-01
CN102137874B (zh) 2015-02-18
MX2011001927A (es) 2011-04-21
ZA201100301B (en) 2011-10-26
ES2638579T3 (es) 2017-10-23
WO2010022736A2 (en) 2010-03-04
US8663640B2 (en) 2014-03-04
KR20110050542A (ko) 2011-05-13
RU2011111746A (ru) 2012-10-10
IL210348A (en) 2016-04-21
EP2331577B1 (en) 2017-06-07
BRPI0918768B1 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
KR101706255B1 (ko) 재조합 항-표피 성장 인자 수용체 항체 조성물
KR101676622B1 (ko) 재조합 항-표피 성장 인자 수용체 항체 조성물
AU2013200209B2 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
RU2488596C2 (ru) Композиции рекомбинантных антител против рецептора эпидермального фактора роста
HK1134826B (en) Recombinant anti-epidermal growth factor receptor antibody compositions
AU2013200210A1 (en) Recombinant anti-epidermal growth factor receptor antibody compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110329

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160121

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160706

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170105

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200131

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200131

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210128

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210128

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220127

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220127

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240109

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20250106

Start annual number: 9

End annual number: 9